7MM COPD market to hit $30.2b in 2033

Triple therapy inhalers are expected to account for 11.3% of the total market.

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM) is expected to reach $30.2b by 2033 at a compound annual growth rate of 10%, according to GlobalData.

The sector’s expansion is attributed to the entry of biologics into the treatment landscape and the continued integration of precision medicine approaches.

Triple therapy inhalers are expected to generate $2.7b in sales in the US alone by 2033, accounting for 11.3% of the total COPD market.

“Biologics and biomarker-driven therapies are poised to redefine COPD treatment,” Asiyah Nawab, Healthcare Analyst at GlobalData, said.

“However, manufacturers must navigate a complex landscape marked by pricing pressures, generic erosion, and evolving treatment guidelines to sustain long-term growth,” Nawab added.

*The 7MM = US, France, Germany, Italy, Spain, the UK, and Japan.